Established 2016|Australia's longest-standing research supplier|Trusted by 4,000+ researchers & labs|Batch-tested · Fast AU-wide dispatch
VCP Australia
Sign In
Peptides — Growth Hormone Axis

Hexarelin

A synthetic hexapeptide growth hormone secretagogue developed in the 1990s and studied in cardiovascular and GH-release research.

Education Hub

Pre-clinical mechanism

Agonist at GHS-R1a and at CD36 in cardiac tissue. Animal models report GH release plus separate, receptor-mediated effects on cardiomyocyte survival under ischaemic conditions.

Key pre-clinical findings

  • Isolated rat heart ischaemia/reperfusion model: cardioprotective effect independent of GH release (Locatelli et al., 1999).

Primary literature

Growth hormone-independent cardioprotective effects of hexarelin

Locatelli V, Rossoni G, Schweiger F, et al. · Endocrinology · 1999

Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.

Research-Use Notice

Products displayed on this website may be intended for laboratory, analytical or research purposes only where applicable. They are not intended to diagnose, treat, cure or prevent any disease. They are not supplied for human or animal consumption unless expressly stated and lawfully permitted. Customers are responsible for understanding and complying with all applicable laws and regulations. Product information is provided for informational purposes only and does not constitute medical advice.

Read Full Disclaimer